Gut Leakage' in Dengue (GLiD)
Gut Leakage and Sonographic Abdominal Changes in Hospitalized Dengue Patients: an Observational Study
Dengue infections are imposing an increasing global burden of disease, particularly in tropical countries such as Bangladesh. The World Health Organization (WHO) has identified Dengue virus as a priority pathogen for the development of medical counter measures because of the high risk of it causing a Public Health Emergency of Intenational Concern (PHEIC). Warning signs for severe dengue, associated with mortality, include gastrointestinal features including abdominal pain, vomiting, and diarrhoea. Multiple alterations may occur in in the gastrointestinal tract that could lead to damaging of the gastrointestinal wall and gut leakage, the translocation of gut metabolites into the bloodstream. Study team hypothesize that gut leakage initiates inflammatory processes underlying the further development of severe dengue, including features associated with plasma leakage.
This study aims to investigate intestinal barrier dysfunction (gut leakage) in dengue infection by detecting the translocation of gut-derived bacteria and their products (Lipopolysaccharides, LPS binding protein, sCD14, I-Fatty Acid Binding Protein) into the bloodstream. Study team will recruit hospitalized adult dengue patients (18 years and older) presenting with warning signs or severe disease in a tertiary care public hospital at Chattogram, Bangladesh. Circulating biomarkers indicative of gut permeability and microbial translocation will be measured to assess their presence and association with disease severity.
Abdominal ultrasonography will be performed to characterize gastrointestinal alterations and determine their correlation with biochemical markers of gut leakage and clinical severity. In addition, study team will analyze the gut bacteriome from stool/ rectal swab of these patients to explore whether dengue infection induces compositional changes in intestinal microbiota and whether such alterations are linked to gut leakage or disease progression.
調査の概要
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
Chattogram Division
-
Chittagong、Chattogram Division、バングラデシュ、4203
- 募集
- Department of Medicine, Chittagong Medical College
-
コンタクト：
- Rabiul Alam Md Erfan Uddin, FCPS
- 電話番号：+8801711129798
- メール：rubelerfan@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
Adult (≥18 years) male and non-pregnant female patients with confirmed dengue (positive NS1 antigen and/or IgM) admitted to the Department of Medicine, Chittagong Medical College Hospital will be recruited. Blood biomarkers will be collected at enrollment for all patients. Those initially classified as non-severe dengue will have no repeat sampling unless they progress to severe disease, in which case a second sample will be obtained within 24 hours. Serum ALT and blood culture will be performed on day 7 of illness. Stool samples will be collected on day 7 from 100 patients for gut microbiota analysis.
Additionally, 10 healthy adult participants (5 male, 5 female) will be recruited from patient attendants. They will undergo a single visit for baseline biomarker sampling and POCUS, serving as healthy controls for comparison.
説明
Inclusion Criteria:
Dengue participants
- Participant/ legally authorised representative willing and able to give informed consent for participation in the study.
- Male or Female, adults ≥18 years
- Diagnosed as a case of Dengue on the basis of clinical features and positive NS1 antigen and/or IgM dengue antibody
- Hospitalized in medicine or dengue ward in Chittagong Medical College Hospital.
- Enrolled within 24 hours of hospitalization.
Healthy participants
- Participant/ legally authorised representative willing and able to give informed consent for participation in the study.
- Male or Female, adults ≥18 years
- Clinically healthy with no acute or chronic illness
- Attendant of a dengue patient (not a patient)
Exclusion Criteria:
Dengue participants
- Unable to provide consent or participate in follow-up procedures
- Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (<3 months) major GI surgery.
- Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.
- Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.
- Pregnancy
Healthy participants
- Unable to provide consent
- Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (<3 months) major GI surgery.
- Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.
- Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.
- Pregnancy
- History of current or recent dengue or other arbo viral infection
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
Severe dengue
All enrolled dengue patients will have blood biomarkers at enrolment whether they present with non-severe or severe dengue.
If participant enrolled as non-severe and do not progress to severe dengue, they will be no second test for biomarkers but if they developed clinical feature of severity, a second biomarker sample will be collected within 24 hours of developing clinical severity.
S ALT and Blood culture will be performed on day 7 of illness for all dengue patients.
Stool will be collected on day 7 of illness from 100 patients for testing gut microbiota.
|
|
Non-severe dengue
All enrolled dengue patients will have blood biomarkers at enrolment whether they present with non-severe or severe dengue.
If participant enrolled as non-severe and do not progress to severe dengue, they will be no second test for biomarkers but if they developed clinical feature of severity, a second biomarker sample will be collected within 24 hours of developing clinical severity.
S ALT and Blood culture will be performed on day 7 of illness for all dengue patients.
Stool will be collected on day 7 of illness from 100 patients for testing gut microbiota.
|
|
Healthy individual
These participants will undergo only one study visit for baseline biomarker sampling, baseline POCUS and will not undergo follow-up.
Their results will serve as healthy control reference values for comparison with biomarker findings in dengue patients.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Level of gut leakage marker in blood and gastrointestinal findings in POCUS
時間枠：On enrollment, day of development of severity if non severe at enrolment, up to 28 days
|
On enrollment, day of development of severity if non severe at enrolment, up to 28 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Document clinical events occurred in dengue patients
時間枠：Through study completion, an average of 28 days
|
Demographic: Age, gender, BMI Clinical: respiratory rate, blood pressure, heart rate, ascites, pleural effusion, any major bleeding, GCS |
Through study completion, an average of 28 days
|
|
Document clinical events occurred in dengue patients
時間枠：Day of enrolment/ 4th or day 7 of illness
|
For mSOFA: SpO2, FiO2 |
Day of enrolment/ 4th or day 7 of illness
|
その他の成果指標
結果測定 |
時間枠 |
|---|---|
|
Level of I-FABP Level of LPS, Level of LBP, Level of sCD14, Positive Blood culture
時間枠：On enrollment in all cases, if clinical severity occur in initial non-severe group, 24 hours within developing severity
|
On enrollment in all cases, if clinical severity occur in initial non-severe group, 24 hours within developing severity
|
|
Alteration of gut microbiota
時間枠：Day seven of illness
|
Day seven of illness
|
|
Organ failure
時間枠：Through study completion, an average of 28 day
|
Through study completion, an average of 28 day
|
|
Development of shock
時間枠：Through study completion, an average of 28 day
|
Through study completion, an average of 28 day
|
|
Detectable fluid collection in abdomen, loss of haustration, loss of normal multi-layered appearance
時間枠：Baseline (within 24 hours of enrollment) and at the time of first development of clinical severity, assessed from enrollment until clinical severity occurs, hospital discharge, death, or up to 7 days of hospitalization, whichever occurs first.
|
Baseline (within 24 hours of enrollment) and at the time of first development of clinical severity, assessed from enrollment until clinical severity occurs, hospital discharge, death, or up to 7 days of hospitalization, whichever occurs first.
|
|
Measurement of gall bladder wall thickness, intestinal wall thickness
時間枠：Baseline (within 24 hours of enrollment) and at the time of first development of clinical severity, assessed from enrollment until clinical severity occurs, hospital discharge, death, or up to 7 days of hospitalization, whichever occurs first.
|
Baseline (within 24 hours of enrollment) and at the time of first development of clinical severity, assessed from enrollment until clinical severity occurs, hospital discharge, death, or up to 7 days of hospitalization, whichever occurs first.
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- VIR26001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。